SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Por:
Segura, PP, Quintela, NV, Garcia, MM, Berron, SD, Sarrio, RG, Gomez, JG, Castano, AG, Martin, LMN, Rubio, OG, Losada, EP
Publicada:
1 sep 2023
Ahead of Print:
1 ago 2023
Resumen:
High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
Filiaciones:
Segura, PP:
Hosp Clin San Carlos, Med Oncol Dept, IdISCC, Madrid, Spain
Quintela, NV:
Catalan Inst Oncol, Med Oncol Dept, Barcelona, Spain
IDIBELL, Oncobell Program, Preclin & Expt Res Thorac Tumors PReTT Grp, Barcelona, Spain
Garcia, MM:
Hosp Mar, Med Oncol Dept, Barcelona, Spain
Hosp Mar, Canc Res Program, Res Inst, Barcelona, Spain
Berron, SD:
Hosp Univ Doctor Josep Trueta, Med Oncol Dept, Unidad Canc Mama & Tumores Cerebrales, Inst Catalan Oncol, Girona, Spain
Sarrio, RG:
Hosp Univ & Politecn La Fe, Med Oncol Dept, Valencia, Spain
Gomez, JG:
Complejo Hosp Univ Orense, Med Oncol Dept, Orense, Spain
Castano, AG:
Hosp Univ Marques de Valdecilla, Med Oncol Dept, Santander, Spain
Martin, LMN:
Complejo Asistencial Univ Salamanca, Med Oncol Dept, Salamanca, Spain
Rubio, OG:
Hosp St Pau & Santa Creu, Med Oncol Dept, Barcelona, Spain
Losada, EP:
IDIBAPS, Hosp Clin & Translat Genom & Targeted Therapies So, Med Oncol Dept, Barcelona, Spain
hybrid, All Open Access; Hybrid Gold
|